12 research outputs found
Gemcitabine plus docetaxel versus docetaxel in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (MBC): A randomized phase III study
No full textMetronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial:a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer
No full textIs metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients?
No full textThe NAME trial:A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer
No full textVinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group
No full textPertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report
No full textPan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
No full text
